GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » Gross Margin %

Icure Pharmaceutical (XKRX:175250) Gross Margin % : 14.30% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Icure Pharmaceutical's Gross Profit for the three months ended in Mar. 2024 was ₩2,279 Mil. Icure Pharmaceutical's Revenue for the three months ended in Mar. 2024 was ₩15,938 Mil. Therefore, Icure Pharmaceutical's Gross Margin % for the quarter that ended in Mar. 2024 was 14.30%.


The historical rank and industry rank for Icure Pharmaceutical's Gross Margin % or its related term are showing as below:

XKRX:175250' s Gross Margin % Range Over the Past 10 Years
Min: -9.4   Med: 20.14   Max: 33.84
Current: 4.32


During the past 10 years, the highest Gross Margin % of Icure Pharmaceutical was 33.84%. The lowest was -9.40%. And the median was 20.14%.

XKRX:175250's Gross Margin % is ranked worse than
94.72% of 984 companies
in the Drug Manufacturers industry
Industry Median: 46.73 vs XKRX:175250: 4.32

Icure Pharmaceutical had a gross margin of 14.30% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Icure Pharmaceutical was 0.00% per year.


Icure Pharmaceutical Gross Margin % Historical Data

The historical data trend for Icure Pharmaceutical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical Gross Margin % Chart

Icure Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.89 20.08 -7.25 -9.40 2.28

Icure Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.09 -4.08 18.92 -17.06 14.30

Competitive Comparison of Icure Pharmaceutical's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icure Pharmaceutical's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's Gross Margin % falls into.



Icure Pharmaceutical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Icure Pharmaceutical's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1297.9 / 56806.335
=(Revenue - Cost of Goods Sold) / Revenue
=(56806.335 - 55508.45) / 56806.335
=2.28 %

Icure Pharmaceutical's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=2279.4 / 15937.952
=(Revenue - Cost of Goods Sold) / Revenue
=(15937.952 - 13658.578) / 15937.952
=14.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Icure Pharmaceutical  (XKRX:175250) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Icure Pharmaceutical had a gross margin of 14.30% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Icure Pharmaceutical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Icure Pharmaceutical (XKRX:175250) Business Description

Traded in Other Exchanges
N/A
Address
7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines